Company intelligence / Profile preview

ATANIS Biotech AG

Bern, Bern, Switzerlandatanis-biotech.com ↗

Ownership: Private
Development stage: Commercial

Overview

ATANIS has developed a novel functional ex vivo mast cell activation test called FAST-PASE® that has outperformed other established clinical methods for identifying allergies in recent diagnostic accuracy studies[2]

Therapeutic areas: Immunology
Modalities: Functional allergy diagnostic assays
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

FAST-PASE

Commercial

Indications: Allergy diagnosis

Partnerships

Excellergy (biotechnology company)[7]

Beyond the preview

Go deeper on ATANIS Biotech AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATANIS Biotech AG.

Explore the full profile